Fig. 1From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancerKaplan-Meier analysis of (a) overall survival and (b) progression-free survival for all patients treated with modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel. CI confidence intervalBack to article page